BENKOWITZ MICHAEL

UTHR President/COO Michael Benkowitz sells entire 14,440-share stake for $6,817,499.44 on 2026-02-23

Michael Benkowitz, President and COO of United Therapeutics, executed 2 separate sales on 2026-02-23 totaling 14,440 shares at $472.13, liquidating his entire equity position for $6,817,499.44. This complete exit is material: Benkowitz held 14,440 shares before the transaction and zero post-transaction, representing a -100.0% reduction in his stake at a company trading at an elevated valuation (P/E 16.03) near its 52-week high. His prior sales at UTHR over the past three weeks (five separate transactions between 2026-02-02 and 2026-02-17) establish a sustained liquidation pattern rather than a one-time event, suggesting a deliberate unwinding of his entire equity position during a period of strong stock performance. The scale and timing of these consecutive dispositions warrant close examination of whether broader strategic or compensation shifts at the company are underway.

UTHR President & COO Michael Benkowitz sells entire 22,500-share position for $10.8M at $480.75 on 2026-02-17

Michael Benkowitz, President and COO of United Therapeutics, executed 2 separate sales totaling 22,500 shares for $10,816,956.00 at a blended average price of $480.75 on 2026-02-17, liquidating his entire holdings (100% net change from pre-transaction position). The sale occurred near the company's 52-week high ($517.13), with the stock trading at $476.05 at filing—only 7.9% below peak. This complete position exit by a senior operating executive is notable given the company's strong fundamentals: $799,500,000.00 in latest quarterly revenue, $338,700,000.00 net income, +23.6% annual revenue growth, and a reasonable 16.12 P/E valuation on a $20.5B market cap. The timing is particularly significant as Benkowitz has sold 5 times at UTHR within the prior three weeks (2026-01-26, 2026-02-02 twice, 2026-02-09 twice), establishing a pattern of consistent liquidation. While the stock is up 2.4% over 30 days and 0.3% over 90 days, investors should monitor whether the repeated and now-complete exit by a key operator signals a material shift in confidence or circumstances at the company.

UTHR President/COO Benkowitz sells entire 22,500-share stake for $10.7M at $474.65

Michael Benkowitz, President and COO of United Therapeutics, liquidated his complete shareholding through 2 separate sales totaling 22,500 shares for $10,679,685.75 at $474.65 per share on 2026-02-09. This represents a 100% reduction in his UTHR holdings, following a pattern of 5 prior sales at this ticker within the past three weeks (2026-01-20 through 2026-02-02). The timing of this exit occurs with the stock trading at $473.20 (near the transaction price and 8.5% below the 52-week high of $517.13), while the company reports strong fundamentals including Q-recent revenue of $799,500,000 and net income of $338,700,000 with annual revenue growth of +23.6%. The complete elimination of a senior executive's stake warrants investor attention, particularly given the recent consecutive selling activity at this ticker and the absence of any offsetting purchases to suggest portfolio rebalancing.

UTHR President/COO Benkowitz sells entire 22,500 share position for $10.6M at $470.95

Michael Benkowitz, President and COO of United Therapeutics, executed 2 separate sales totaling 22,500 shares for $10,596,429.00 at a blended average price of $470.95 on 2026-02-02, completely liquidating his shareholding position. This represents a 100% reduction in his pre-transaction holdings of 22,500 shares, signifying a complete exit. The transaction occurred while the stock traded at $478.27 currently, placing it -7.5% from its 52-week high of $517.13 and showing a -3.7% decline over the past 30 days despite a +6.9% gain over 90 days. His prior activity at UTHR shows 5 recent sells in early-to-mid January 2026 (all within the past two weeks), establishing a pattern of liquidation activity by a senior executive in a company with solid fundamentals: $799.5M quarterly revenue, $338.7M net income, 23.6% annual revenue growth, and a moderate P/E of 16.19. The complete elimination of an officer's shareholding warrants investor attention given the company's $20.6B market cap and the senior executive's position.

UTHR President & COO Michael Benkowitz sold entire 14,625-share stake ($6.8M) across 14 transactions at blended average $464.66 on 2026-01-20.

Michael Benkowitz, President and COO of United Therapeutics, executed a complete liquidation of his equity position on January 20, 2026, selling 14,625 shares through 14 separate transactions for a total of $6,795,626.74. The sales were executed at prices ranging from $456.87 to $470.76, with a blended average price of $464.66, just below the current price of $467.30. This represents a 100% reduction in his holdings at the company. The complete exit by a senior executive merits investor attention, particularly given the company's strong recent fundamentals: revenue of $799,500,000.00 in the latest quarter, net income of $338,700,000.00, annual revenue growth of +23.6%, and a relatively modest P/E of 15.82. The timing of this full liquidation—a significant shift from his prior trading activity—should be monitored for additional context around executive strategy and confidence in the company's near-term outlook.

UTHR President/COO Michael Benkowitz sold entire 30,375-share position for $14.3M over two days (Jan 20–26, 2026)

Michael Benkowitz, UTHR's President and COO, executed 16 separate sales totaling 30,375 shares for $14,277,113.92, reducing his holdings from 30,375 shares to 0 shares post-transaction (−100.0% of pre-transaction holdings). The sales occurred across two dates—primarily on 2026-01-20 in smaller tranches at prices ranging from $456.87 to $470.76, followed by two larger blocks on 2026-01-26 at $471.91 per share. The blended average price of $470.03 is only 0.6% above the current price of $467.30, reflecting execution near current market levels. A complete liquidation of an executive's shareholding warrants scrutiny, particularly given United Therapeutics' strong fundamental position (P/E of 15.82, +23.6% annual revenue growth, $338.7M net income on $799.5M quarterly revenue) and proximity to 52-week highs; prior trading outcomes for this insider across his full cross-ticker history remain unpredictable (0 well-timed outcomes measurable from 5 prior same-ticker sales). The multi-tranche structure and price progression suggest systematic liquidation rather than a single market-driven decision point.

UTHR President and COO Benkowitz liquidates entire 22.5K share position for $10.8M on 2026-01-12

Michael Benkowitz, President and COO of United Therapeutics, executed two separate sales totaling 22,500 shares at $479.51 per share for $10,788,876.00 on 2026-01-12, entirely liquidating his holdings at this company. The complete exit—100.0% reduction from 22.5K shares—stands notably against UTHR's strong operational performance: annual revenue growth of +23.6%, net income of $338.7M on revenue of $799.5M, and a P/E of 16.14 in a market cap of $20.5B. While the stock is currently trading at $476.86 (down 3.5% over 30 days and down 7.8% from its 52-week high of $517.13), the transaction was executed near recent peaks. The executive's prior activity at UTHR shows five sales on 2026-01-05 (outcomes not yet measurable), indicating a sustained exit pattern in the past week. Investors should note this is a complete position exit by a senior operator at a company with strong recent growth metrics and profitability.

President/COO Benkowitz sells entire 7.9K share position in UTHR for $3.8M across 14 transactions on 2026-01-05

Michael Benkowitz, President and COO of United Therapeutics Corp, executed 14 separate sales totaling 7,875 shares for $3,838,084.96 on 2026-01-05, completely liquidating his entire position in the company. The multi-tranche execution across a range of prices (blended average $487.38) reduced his holdings from 7.9K shares to zero. The timing occurs when the stock trades at $503.69, near its 52-week high of $517.13 and up 13.1% over the prior 90 days. Given that Benkowitz holds the President and COO title—a senior operational role directly accountable for company performance—a complete exit of his equity stake warrants scrutiny by investors assessing management's confidence in forward prospects and capital allocation priorities.

UTHR President/COO Michael Benkowitz sold entire 14,625-share position ($7.1M) on 2026-01-05 at blended avg $487.38

Michael Benkowitz, President and COO of United Therapeutics, liquidated his complete equity stake through 14 separate sales totaling 14,625 shares for $7,127,877.16 on a single trading day (2026-01-05). The position was exited across a narrow price range ($480.68–$493.47), with a blended average price of $487.38, slightly below the current price of $503.69. This is a complete position exit by a senior executive of a profitable company (net income $338.7M, P/E 17.05, +23.6% annual revenue growth), reducing his holdings from 14.6K shares to zero. The transaction structure—multiple smaller tranches executed same-day—and the loss of conviction signal warrant close monitoring of company-specific or personal circumstances that prompted the departure of equity exposure by an operating executive.

President and COO Michael Benkowitz sells entire UTHR position of 22,500 shares for $11,312,709.75 on 2025-12-29

Michael Benkowitz, President and COO of United Therapeutics, executed 2 separate sales on 2025-12-29, liquidating his complete holdings of 22,500 shares for $11,312,709.75 at $502.79 per share. This represents a 100% reduction in his holdings at the company. The sales occurred near the 52-week high of $517.13 (current price $496.19 is -4.0% from that peak), and follow five other sales by Benkowitz at UTHR dated 2025-12-22, suggesting an active disposition window. The company shows strong fundamentals with revenue of $799,500,000.00, net income of $338,700,000.00, and 23.6% annual revenue growth, alongside a reasonable P/E of 16.80. The complete exit by a senior executive warrants investor scrutiny into the timing and circumstances of this liquidation.